[ Price : $8.95]
Amgen says its Repatha met the primary endpoints in a landmark Phase 3 trial, making it the only PCSK9 inhibitor to demonstrate a ...[ Price : $8.95]
FDA posts a four-item Form FDA 483 that was issued to Laboratorios Grifols after a 7/2024 inspection of the firms drug manufacturi...[ Price : $8.95]
FDA accepts for review a Daiichi Sankyo and AstraZeneca supplemental BLA for Enhertu use followed by paclitaxel, trastuzumab, and ...[ Price : $8.95]
FDA approves Jazz Pharmaceuticals Zepzelca (lurbinectedin) in combination with Genentechs Tecentriq or Tecentriq Hybreza for the m...[ Price : $8.95]
FDA grants Bristol Myers Squibb fast-track status for its investigational Alzheimers therapy BMS-986446.[ Price : $8.95]
FDA issues a report highlighting Sentinel System activities and achievements between 2022 and 2024.[ Price : $8.95]
FDA and Vanda agree to a series of actions to resolve their disputes over the companys Hetlioz and tradipitant.[ Price : $8.95]
A CDRH Learn module reviews the Quality Management System Regulation requirements for medical device manufacturers and the benefit...